HDAC9 and prostate cancer: These results suggest that HDAC inhibiters lead to hyper-acetylation in histone 3 on gene promoters by repressing the activity but not reducing amount of HDACs on promoter of target genes such as vimentin, ZEB1, Slug and MMP2, resulting in EMT signatures in prostate cancer cell lines (Fig. 7).